Altheus Therapeutics Inc.
Expecting chemical synergy to improve ulcerative colitis
This article was originally published in Start Up
Executive Summary
If you can’t beat them, join them. Looks like the backers of Altheus Therapeutics Inc. see sound business sense in this homily: the start-up is working to create a potent new treatment for ulcerative colitis by combining N-acetylcysteine, an anti-inflammatory compound, with the aspirin derivative mesalamine, which for decades has been the front-line therapy for the condition.
You may also be interested in...
VC-backed GI Start-Ups See Opportunity In IBS
Private companies developing drugs for gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome hope to take advantage of a resurging interest in the space after linaclotide developer Ironwood Pharmaceuticals has shown its novel, locally acting guanylate cyclise type-C agonist is efficacious in four Phase III trials. We profile four such hopefuls in this issue: Altheus Therapeutics, AltheRx Pharmaceuticals, Aldrex and Second Genome.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.